Nyxoah SA（NYXH）股票分析

AI 分析 of Nyxoah SA (NYXH)

持有

Nyxoah SA (NYXH) is currently not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $0.88, significantly down from its 52-week high of $5.92, reflecting an 80.44% year-to-date decline. Although the company reported a 21% revenue growth in Q2 2026, its forward P/E is at 0, indicating no earnings growth expected in the near term. The RSI is at 30.874, suggesting it is oversold, but the overall sentiment remains cautious due to recent downgrades from analysts, with Cantor Fitzgerald lowering its price target to $3 from $6. The main risk is the company's ongoing net losses, which reached €32.96 million in Q2 2026, indicating financial instability. Therefore, while there are some positive indicators, the risks outweigh the potential for immediate gains, making it prudent to hold rather than buy at this time.

估值指标

Nyxoah SA（NYXH）当前预期市盈率为 0.00，5 年平均预期市盈率为 -4.19。

预期市盈率

高估

5 年均值 P/E

-4.19

当前P/E

0.00

高估

-0.85

低估

-7.52

预期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-3.12

当前EV/EBITDA

-0.42

高估

-0.25

低估

-5.99

预期市销率

合理

5 年均值 P/S

23.23

当前P/S

1.26

高估

45.85

低估

0.61

Alphio AI 对 NYXH 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%NYXH

$9.24

情景价格

基

基准

基准 · 50%NYXH

$7.86

情景价格

悲

悲观

悲观 · 25%NYXH

$7.48

情景价格

持有 NYXH 的大户

P

Pentwater Capital Management LP

+ 持有NYXH

-3.88%

3个月收益率

NYXH 常见问题 —— 由 Alphio AI 解答

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin. It operates in the Healthcare sector.

Nyxoah SA (NYXH) is currently not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $0.88, significantly down from its 52-week high of $5.92, reflecting an 80.44% year-to-date decline. Although the company reported a 21% revenue growth in Q2 2026, its forward P/E is at 0, indicating no earnings growth expected in the near term. The RSI is at 30.874, suggesting it is oversold, but the overall sentiment remains cautious due to recent downgrades from analysts, with Cantor Fitzgerald lowering its price target to $3 from $6. The main risk is the company's ongoing net losses, which reached €32.96 million in Q2 2026, indicating financial instability. Therefore, while there are some positive indicators, the risks outweigh the potential for immediate gains, making it prudent to hold rather than buy at this time.